reply to @Jdmoney
My apologies, "unreasonably" is probably too strong a term.
I understood that the Ex US value for cardioprotection anticancer is arrived at by doubling the US number and then allowing a bit more upside for increased anthracycline use exUS. The use exUS is 95% (not 60% or 70%).
Also any underestimation made in the US market is carried over into the Global valuation. The US assumes 25% reduction in anthracycline use over the next 10 years, all the reports I found on the global doxorubicin market expect a CAGR of around 6% over the next 5 - 10 years.
My point is that I agree with others who have mentioned the Triangle report is conservative and I haven't seen anything yet to refute LTs valuations.
If I have misunderstood the Triangle report or are making incorrect assumptions, more than happy to be corrected.
- Forums
- ASX - By Stock
- RAC
- Why Analysts Believe RAC is “Highly Undervalued”
Why Analysts Believe RAC is “Highly Undervalued”, page-113
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.83 |
Change
0.020(1.11%) |
Mkt cap ! $310.7M |
Open | High | Low | Value | Volume |
$1.81 | $1.83 | $1.79 | $142.0K | 78.77K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 641 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.810 |
3 | 7009 | 1.790 |
1 | 450 | 1.780 |
2 | 16392 | 1.770 |
2 | 1018 | 1.765 |
Price($) | Vol. | No. |
---|---|---|
1.830 | 558 | 1 |
1.840 | 4000 | 2 |
1.845 | 2746 | 1 |
1.860 | 1000 | 1 |
1.870 | 1200 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online